Best Researcher Award

Jaume Alijotas-Reig is a Spanish physician, clinical immunologist, researcher, educator, and academic leader affiliated with Vall d’Hebron University Hospital, Barcelona, Spain. His professional activities encompass systemic autoimmune diseases, antiphospholipid syndrome, reproductive immunology, internal medicine, rheumatology, and clinical immunology. Through extensive scientific publications, postgraduate supervision, international collaborations, and leadership roles in major European and global research initiatives, he has contributed substantially to the advancement of autoimmune disease research and clinical practice.[1][2]

Jaume Alijotas-Reig currently serves as Senior Consultant in the Systemic Autoimmune Diseases Unit at Vall d’Hebron Barcelona Hospital Campus, Head of the Systemic Autoimmune Diseases Research Unit at the Vall d’Hebron Research Institute (VHIR), Full Professor of Medicine at the Universitat Autònoma de Barcelona, Director of Postgraduate Studies in the Department of Medicine, and Chair of the UAB Cathedra of Reproductive Medicine and Immunology. His multidisciplinary career integrates clinical care, scientific research, postgraduate education, and international scientific leadership.[1]

Abstract

This article evaluates the academic profile, scientific productivity, educational leadership, and international research contributions of Jaume Alijotas-Reig in relation to recognition through the Best Researcher Award at the Top Teachers Awards. His career demonstrates sustained engagement in translational medicine, autoimmune diseases, reproductive immunology, antiphospholipid syndrome, and clinical research methodology. With extensive publication output, significant citation impact, postgraduate supervision, and leadership within international scientific organizations, his work reflects a substantial contribution to contemporary medical science.[1][3]

Keywords

Immunology; Autoimmunity; Antiphospholipid Syndrome; Miscarriages; Systemic Lupus Erythematosus; Biomaterials; Adverse Reactions; Immunosuppressives; Rheumatology; Reproductive Biology.

Introduction

Jaume Alijotas-Reig has developed a multidisciplinary academic career combining internal medicine, clinical immunology, rheumatology, obstetrics-related immunology, and autoimmune disease research. He obtained his medical degree with special distinction from the Faculty of Medicine at the Universitat Autònoma de Barcelona and subsequently completed specialist training in Internal Medicine at Vall d’Hebron University Hospital. His doctoral and postgraduate studies further strengthened his expertise in medicine and clinical immunology.[1]

His research has focused particularly on antiphospholipid syndrome, systemic autoimmune diseases, reproductive immunology, pregnancy complications associated with autoimmune disorders, and evidence-based diagnostic criteria. These research themes have contributed to both academic literature and clinical guideline development.[4][5]

Research Profile

According to Scopus data, Professor Jaume Alijotas-Reig has authored 168 indexed documents and accumulated more than 6,110 citations with an h-index of 41, demonstrating sustained influence within biomedical and clinical research communities.[1]

• Senior Consultant, Systemic Autoimmune Diseases Unit, Vall d’Hebron Barcelona Hospital Campus.
• Head, Systemic Autoimmune Diseases Research Unit, Vall d’Hebron Research Institute (VHIR).
• Full Professor of Medicine, Universitat Autònoma de Barcelona.
• Director of Postgraduate Studies, Department of Medicine.
• Chair, UAB Cathedra of Reproductive Medicine and Immunology.

Research Contributions

Professor Jaume Alijotas-Reig has contributed to the understanding of autoimmune mechanisms, antiphospholipid antibodies, reproductive failure associated with immune dysfunction, systemic lupus erythematosus, and immunomodulatory therapies. His work has supported ongoing efforts to improve diagnostic standardization and evidence-based clinical management of autoimmune diseases.[3][4]

• General Coordinator of the EUROAPS Study Group (EUROFORUM-APS).
• Steering Committee Member, European Forum on Antiphospholipid Antibodies.
• Participant in CORA and Skylark international projects.
• Member of the EULAR-ReHFaP Group.
• Chair, ISTH/EUROFORUM Taskforce for APS Diagnostic Criteria Guidelines.
• Co-Chair, ICAPA Barcelona 2028.
• Holder of two patents and contributor to one spin-off initiative.

Publications

Jaume Alijotas-Reig’s recent publications advance antiphospholipid syndrome research, emphasizing diagnostic standardization, IgM antibody relevance, and ACR/EULAR criteria evaluation, contributing to clinical decision-making and guideline development.[3][4][5]

Professor Jaume Alijotas-Reig has published approximately 175 peer-reviewed indexed articles, with additional manuscripts under publication review. Recent contributions include investigations into antiphospholipid syndrome classification, diagnostic biomarkers, and clinical appraisal of updated international criteria.[3][5]

1. The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification (2025).
2. IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review.
3. Are the 2023 ACR/EULAR classification criteria a step forward in the management of antiphospholipid syndrome? A literature-based and clinical practice appraisal.

Research Impact

The impact of Professor Jaume Alijotas-Reig’s research extends beyond publication metrics. He has supervised 12 doctoral theses, tutored 16 doctoral candidates, and supervised approximately 75 master’s theses. His expertise has been recognized through invitations to review manuscripts for high-impact journals including The Lancet, Blood, Circulation, Annals of Rheumatic Diseases, Human Reproduction, Rheumatology, and Clinical Immunology among others.[1]

His scholarly influence is additionally reflected in leadership activities across European and international scientific organizations dedicated to autoimmune disease research, thrombosis, reproductive immunology, and evidence-based clinical practice.[5]

Award Suitability

Evaluation against common academic recognition criteria indicates strong alignment with the objectives of a Best Researcher Award. Factors supporting suitability include sustained publication productivity, citation impact, interdisciplinary research leadership, postgraduate mentorship, scientific service, international collaboration, and contribution to clinical guideline development. His record of scientific achievements, combined with educational leadership and institutional responsibilities, demonstrates a comprehensive academic profile suitable for recognition by the Top Teachers Awards.[1][2]

Conclusion

Jaume Alijotas-Reig represents an established academic physician-scientist whose work has contributed significantly to autoimmune disease research, reproductive immunology, and clinical medicine. Through leadership, scholarship, mentorship, and international scientific engagement, he has developed a distinguished professional profile. Based on available scholarly indicators and documented achievements, his career reflects many of the characteristics commonly associated with recipients of major academic research awards.[1][5]

External Links

• Scopus Author Profile
• ORCID Profile
• Web of Science Profile
• Sci Profiles
• Award Website

References

1. Elsevier. (n.d.). Scopus author details: Jaume Alijotas-Reig, Author ID 55965908100. Scopus. https://www.scopus.com/pages/authors/55965908100
2. ORCID. (n.d.). ORCID Profile: Jaume Alijotas-Reig. https://orcid.org/0000-0002-9212-3619
3. Anunciación-Llunell A., Alijotas-Reig J, Marques-Soares J., Ockova M., et al. (2025). The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification. Research and Practice in Thrombosis and Haemostasis. DOI: https://doi.org/10.1016/j.rpth.2025.102967
4. Očková M., Alijotas-Reig J, Anunciación-Llunell A., Andrada C., et al. IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review. Journal of Clinical Medicine. DOI: https://doi.org/10.3390/jcm14207164
5. Alijotas-Reig J., Marques-Soares J., Esteve-Valverde E., et al. (2025). Are the 2023 ACR/EULAR classification criteria a step forward in the management of antiphospholipid syndrome? A literature-based and clinical practice appraisal. Autoimmunity Reviews. DOI: https://doi.org/10.1016/j.autrev.2025.103956